




Fig. S1 Validation of HRD threshold derived from cohort 1 in cohort 2 (A). ROC curves illustrating the performance of the HRD score in predicting *BRCA* mutation status in cohort 1 and cohort 2. **(B).** Pie chart depicting the distribution of subgroups in cohort 2, stratified by HRD threshold of 43. ROC: receiver operating characteristic; HRD: homologous recombination deficiency; AUC: the area under the curve; CI: 95% confidence interval.




Figure. S2 Comparison of genomic biomarkers between HRD-high and HRD-low in OV patient




Figure. S3 Comparison of immune-related genes between HRD-high and HRD-low in OV patients




Figure. S4 Kaplan-Meier estimates of overall survival for patients with high and low STAT1 expression and HLA-I signature scores in the TCGA-OV cohort




Figure. S5 Comparison of immune-related signatures between HRD-high and HRD-low in OV patients




Figure. S6 Comparison of bTMB and bMSI value between HRD-high and HRD-low in baseline samples of OV patients